{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:47:07Z","timestamp":1790034427159,"version":"4.0.1"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["2D43TW009744"],"award-info":[{"award-number":["2D43TW009744"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R21TW012635"],"award-info":[{"award-number":["R21TW012635"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24IVPHA1297559"],"award-info":[{"award-number":["24IVPHA1297559"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>An increase in the prevalence of HIV drug resistance (HIVDR) has been reported in recent years, especially in persons on non-nucleoside reverse transcriptase inhibitors (NNRTIs) due to their low genetic barrier to mutations. However, there is a paucity of epidemiological data quantifying HIVDR in the era of new drugs like dolutegravir (DTG) in sub-Saharan Africa. We, therefore, sought to determine the prevalence and correlates of viral load (VL) suppression in adult people with HIV (PWH) on a fixed-dose combination of tenofovir disoproxil fumarate\/lamivudine\/dolutegravir (TLD) or tenofovir alafenamide\/emtricitabine\/dolutegravir (TAFED) and describe patterns of mutations in individuals failing treatment.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>We conducted a cross-sectional study among 384 adults living with HIV aged \u226515 years between 5<jats:sup>th<\/jats:sup>June 2023 and 10<jats:sup>th<\/jats:sup>August 2023. Demographic, laboratory and clinical data were collected from electronic health records using a data collection form. Viral load suppression was defined as plasma HIV-1 RNA VL of &lt;1000 copies\/ml after being on ART for \u2265 6 months. SPSS version 22 to analyze the data. Descriptive statistics and logistic regression were the statistical methods used.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>The median (interquartile range (IQR)) age was 22 (IQR 18, 38) years, and 66.1% (n = 254) were females. VL suppression was 90.4% (n = 347); (95% confidence interval (CI) 87.6%-93.6%) after switching to TLD\/TAFED. Among the virally suppressed, the majority (67.1%, n = 233) were female. Those who missed \u22652 doses in the last 30 days prior to the most recent review were less likely to attain viral suppression compared to those who did not miss any dose (adjusted odds ratio (AOR) 0.047; 95% CI 0.016\u20130.136; p&lt;0.001). Four participants had resistance mutations to lamivudine and tenofovir. The most common NRTI mutations were M184MV and K65R while K101E was the most common NNRTI mutation.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>Our findings show that viral suppression was high after switching to TLD\/TAFED; but lower than the last 95% target of the UNAIDS. Adherence to antiretroviral therapy was a significant correlate of VL suppression. We, therefore, recommend prompt switching of PWH to TLD\/TAFED regimen and close monitoring to enhance adherence to therapy.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0308869","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T18:03:55Z","timestamp":1725645835000},"page":"e0308869","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD\/TAFED in Zambia"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-2422","authenticated-orcid":true,"given":"Emmanuel L.","family":"Luwaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lackson","family":"Mwape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1924-6819","authenticated-orcid":true,"given":"Kaole","family":"Bwalya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chileleko","family":"Siakabanze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson M.","family":"Hamooya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepiso K.","family":"Masenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"pone.0308869.ref001","doi-asserted-by":"crossref","first-page":"e0154893","DOI":"10.1371\/journal.pone.0154893","article-title":"What Is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach","volume":"11","author":"J Stover","year":"2016","journal-title":"PLoS ONE"},{"key":"pone.0308869.ref002","unstructured":"HIV_DrugRes_FINAL_01_04_19_online.pdf. Available: https:\/\/www.afro.who.int\/sites\/default\/files\/2019-04\/HIV_DrugRes_FINAL_01_04_19_online.pdf."},{"key":"pone.0308869.ref003","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1097\/QAD.0000000000002983","article-title":"The Joint United Nations Programme on HIV\/AIDS 95\u201395\u201395 targets: worldwide clinical and cost benefits of generic manufacture","volume":"35","author":"K Heath","year":"2021","journal-title":"AIDS"},{"key":"pone.0308869.ref004","unstructured":"ZAMPHIA-2021-Final-Report-December-2023.pdf. Available: https:\/\/www.zamstats.gov.zm\/wp-content\/uploads\/2023\/12\/ZAMPHIA-2021-Final-Report-December-2023.pdf."},{"key":"pone.0308869.ref005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3851\/IMP3299","article-title":"Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia","volume":"24","author":"FP Hudson","year":"2019","journal-title":"Antivir Ther"},{"key":"pone.0308869.ref006","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"KJ Lepik","year":"2017","journal-title":"AIDS"},{"key":"pone.0308869.ref007","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijantimicag.2018.01.009","article-title":"Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations","volume":"51","author":"E S\u00f6rstedt","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0308869.ref008","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"RK Gupta","year":"2012","journal-title":"Lancet"},{"key":"pone.0308869.ref009","doi-asserted-by":"crossref","first-page":"S801","DOI":"10.1093\/infdis\/jix402","article-title":"The World Health Organization\u2019s Response to Emerging Human Immunodeficiency Virus Drug Resistance and a Call for Global Action","volume":"216","author":"S Bertagnolio","year":"2017","journal-title":"J Infect Dis"},{"key":"pone.0308869.ref010","doi-asserted-by":"crossref","first-page":"23259582211022463","DOI":"10.1177\/23259582211022463","article-title":"Retrospective Review of Virologic and Immunologic Response in Treatment-Experienced Patients on Third-Line HIV Therapy in Lusaka, Zambia","volume":"20","author":"PM Zulu","year":"2021","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"pone.0308869.ref011","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"TTS Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pone.0308869.ref012","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s12889-022-12738-4","article-title":"Exploring the mechanisms behind HIV drug resistance in sub-Saharan Africa: conceptual mapping of a complex adaptive system based on multi-disciplinary expert insights","volume":"22","author":"A Kiekens","year":"2022","journal-title":"BMC Public Health"},{"key":"pone.0308869.ref013","volume-title":"Global report on early warning indicators of HIV drug resistance: technical report","author":"World Health Organization","year":"2016"},{"key":"pone.0308869.ref014","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0000000000002908","article-title":"High Level of HIV Drug Resistance and Virologic Nonsuppression Among Female Sex Workers in Ethiopia: A Nationwide Cross-Sectional Study","volume":"89","author":"DA Arimide","year":"2022","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"pone.0308869.ref015","volume-title":"HIV drug resistance strategy. 2021 update.","author":"World Health Organization","year":"2021"},{"key":"pone.0308869.ref016","volume-title":"HIV drug resistance strategy. 2021 update.:","author":"World Health Organization","year":"2021"},{"key":"pone.0308869.ref017","volume-title":"Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact","author":"World Health Organization","year":"2022"},{"key":"pone.0308869.ref018","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1016\/S2352-3018(18)30093-6","article-title":"Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research","volume":"5","author":"J Dorward","year":"2018","journal-title":"Lancet HIV"},{"key":"pone.0308869.ref019","first-page":"e01643","article-title":"Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study","volume":"66","author":"M Underwood","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0308869.ref020","volume-title":"UNAIDS. Integration of mental health and HIV interventions: key considerations.","author":"World Health Organization","year":"2022"},{"key":"pone.0308869.ref021","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/QAD.0000000000002936","article-title":"Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen","volume":"35","author":"CM Keene","year":"2021","journal-title":"AIDS Lond Engl"},{"key":"pone.0308869.ref022","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1093\/jac\/dkaa355","article-title":"Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda","volume":"75","author":"E Ndashimye","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"pone.0308869.ref023","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000002979","article-title":"Dolutegravir\/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV","volume":"35","author":"C-P Rolle","year":"2021","journal-title":"AIDS"},{"key":"pone.0308869.ref024","unstructured":"Zambia-Consolidated-Guidelines-for-Treatment-and-Prevention-of-HIV-Infection-2020.pdf. Available: https:\/\/www.moh.gov.zm\/wp-content\/uploads\/filebase\/Zambia-Consolidated-Guidelines-for-Treatment-and-Prevention-of-HIV-Infection-2020.pdf."},{"key":"pone.0308869.ref025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/QAI.0000000000001678","article-title":"Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment","volume":"78","author":"E Bernal","year":"2018","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"pone.0308869.ref026","doi-asserted-by":"crossref","first-page":"e1002820","DOI":"10.1371\/journal.pmed.1002820","article-title":"The missed potential of CD4 and viral load testing to improve clinical outcomes for people living with HIV in lower-resource settings","volume":"16","author":"PD Ehrenkranz","year":"2019","journal-title":"PLoS Med"},{"key":"pone.0308869.ref027","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12985-023-02245-2","article-title":"HIV viral suppression at different thresholds and duration of treatment in the dolutegravir treatment era in Sierra Leone: a nationwide survey","volume":"20","author":"J-W Song","year":"2023","journal-title":"Virol J"},{"key":"pone.0308869.ref028","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/ijerph19031085","article-title":"Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study","volume":"19","author":"RT Buju","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"pone.0308869.ref029","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","article-title":"Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study","volume":"9","author":"B Schramm","year":"2022","journal-title":"Lancet HIV"},{"key":"pone.0308869.ref030","first-page":"13","article-title":"High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam","author":"B Gm","year":"2023","journal-title":"Sci Rep"},{"key":"pone.0308869.ref031","doi-asserted-by":"crossref","first-page":"dlab050","DOI":"10.1093\/jacamr\/dlab050","article-title":"High level of HIV drug resistance informs dolutegravir roll-out and optimized NRTI backbone strategy in Mozambique","volume":"3","author":"V Carnimeo","year":"2021","journal-title":"JAC-Antimicrob Resist"},{"key":"pone.0308869.ref032","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11904-018-0377-0","article-title":"Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring","volume":"15","author":"JR Castillo-Mancilla","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"pone.0308869.ref033","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s10461-017-1724-7","article-title":"Correlation of Adherence by Pill Count, Self-report, MEMS and Plasma Drug Levels to Treatment Response Among Women Receiving ARV Therapy for PMTCT in Kenya","volume":"22","author":"V Mudhune","year":"2018","journal-title":"AIDS Behav"},{"key":"pone.0308869.ref034","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1097\/QAD.0000000000003082","article-title":"Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era","volume":"35","author":"SM McCluskey","year":"2021","journal-title":"AIDS Lond Engl"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T21:28:19Z","timestamp":1732742899000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308869"}},"subtitle":[],"editor":[{"given":"Anne","family":"Kapaata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0308869","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}